Practice recommendations based on low, very low, and missing evidence

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 1, 2007, Pages 11-12

  Coyne, Daniel W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC KIDNEY FAILURE; EVIDENCE BASED MEDICINE; HUMAN; NEPHROLOGY; PRACTICE GUIDELINE; REVIEW; STANDARD;

EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHROLOGY; PRACTICE GUIDELINES;

EID: 34247376118     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02980906     Document Type: Article

References (14)

1. Van Wyck D, Eckardt K-U, Uhlig K, Rocco M, Levin A: Appraisal of evidence and control of bias in the Kidney Disease Outcomes Quality Initiative guideline development process. Clin J Am Soc Nephrol 2: 8-10, 2007
2. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 47: S16-S85, 2006
3. Gellene D: Strengthening bones, raising questions; Amgen's ties to kidney research are suspect to some experts. Los Angeles Times Home Edition 2004, pp C1, April 5, 2004
4. Coyne D: Influence of industry on renal guideline development. Clin J Am Soc Nephrol 2: 3-7, 2007
5. Clinical Practice Guidelines for Anemia in Chronic Kidney Disease: Confidential Review Draft. K/DOQI Anemia in CKD, New York, National Kidney Foundation, 2005, pp 1-243
6. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 339: 578-583, 1998
7. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK: The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7: 2654-2657, 1996
8. Lin J, Chang M, Tan D, Leu M: Short-term small-dose intravenous iron trial to detect functional iron deficiency in dialysis patients. Am J Nephrol 21: 91-97, 2001
9. Mittman N, Sreedhara R, Mushnick R, Chattopadhyay J, Zelmanovic D, Vaseghi M, Avram MM: Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 30: 912-922, 1997
10. Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, Gammaro L, Brocco G, Restivo G, Bernich P, Lupo A, Maschio G: The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16: 1416-1423, 2001
11. Low CL, Bailie GR, Eisele G: Sensitivity and specificity of transferrin saturation and serum ferritin as markers of iron status after intravenous iron dextran in hemodialysis patients. Ren Fail 19: 781-788, 1997
12. Chuang CL, Liu RS, Wei YH, Huang TP, Tarng DC: Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant 18: 370-377, 2003
13. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11: 530-538, 2000
14. Richardson D, Bartlett C, Will EJ: Optimizing erythropoietin therapy in hemodialysis patients. Am J Kidney Dis 38: 109-117, 2001